BCRX--Pure short-:Investors are not looking the risk in this stock.
On July 22, 2013, BioCryst shares skyrocketed 50% after the company announced that its Phase 1 clinical trial testing BCX4161, on healthy volunteers met all of its objectives. The clinical trial found that not only was BCX4161 safe and well tolerated, but researchers noted that a 400mg dose of the investigational drug three times daily could produce blood concentration levels sufficient to get a clinical effect in patients with HAE.
In healthy volunteers, the study found that BCX4161 inhibited , kallikrein, that can facilitate dramatic swelling in HAE patients. This swelling can be potentially lethal if it occurs near an airway.
Researchers concluded that the safety, tolerability, drug exposure and on-target kallikrein inhibition results of this Phase 1 trial strongly supported advancing the development program into a Phase 2a study in HAE patients.
On August 1, 2013, BioCryst disclosed in a regulatory filing that on July 31, the company was notified by the FDA that the clinical hold placed on BCX 4161 has been removed. The FDA advised BioCryst that the complete response letter (CRL) satisfactorily addressed the agency's concerns. This notification by the FDA provides BioCryst the ability to initiate BCX 4161 clinical trials in the United States.
My Analysis: Revenue keep decreasing and Phase II trial with higher dose may have lots of Toxicity.Phase I with low dose does not mean any thing If you are moving the stock on the basis of Phase I then it is Insane and pure stupid.
Don't be bad your losing cause you shorted the stock. I wish I didnt sell half my position last tuesday, I wish I purchased more on Wed and Thurs but I didnt. I cant be mad and negative towards those that did. The stock is on a roll and only more growth to come. Just remember that in that same article it states:
"After a bad news spree, the future is looking brighter for the company. In May, BioCryst reported that its recent interactions with the FDA defined a pathway to file a peramivir NDA for regulatory approval in the United States. There is a dire need for new influenza antivirals. These agents have not been seen as financially attractive drugs by the pharmaceutical industry, despite the many victims stricken with seasonal and pandemic influenza every year.
On July 31, the FDA removed its hold on BCX 4161. BioCryst may now conduct clinical trials in the United States to further the development of the drug.
According to Biocryst CEO Stonehouse, "The core value in our company is in the HAE program, and our goal is to be a leader in the prevention of HAE attacks."
In the past, most investors thought peramivir was the product candidate that would make BioCryst a lucrative investment, but the company is extremely enthusiastic about BCX4161."
"My Analysis: Revenue keep decreasing and Phase II trial with higher dose may have lots of Toxicity.Phase I with low dose does not mean any thing If you are moving the stock on the basis of Phase I then it is Insane and pure stupid"
do you guys just take a glance at the chart, pull up the latest news, then make a 2 minute decision?